Press Releases

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing Phase 2 trial (IO102-012/KEYNOTE-764) of its lead cancer therapeutic vaccine, IO102, in non-small cell lung cancer (NSCLC).  In this randomized trial, IO102 is being tested in combination with Merck's anti-PD1 therapy, Keytruda (pembrolizumab) as

Eminence Business Media proudly presents the “Pharma GMP, GCP & Quality Management 2020” scheduled for April 16th – 17th, 2020 at Hotel Westin Mumbai Garden City. The summit is bringing together the senior practitioners across the pharmaceutical industry to discover the best strategies & approaches in order to remain competitive while meeting the industry's ever-evolving quality standards. For this constantly evolving business turf, this Summi

Eli Lilly and Company  announced the successful completion of its acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. The acquisition of Dermira also exp

Tocagen Inc., and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. Upon stockholder approval, the combined comp

Improving adherence to medication via smarter, patient-centric pharmaceutical packaging and extracting further value from existing medicines and delivery devices are two of the latest key strategies aimed at reducing waste and protecting the bottom line, according to experts at the recent Pharmapack Europe (#pharmapackeu). The event is widely seen as an excellent yardstick of the industry’s prospects for the year ahead. Encouragingly, the event played host a record 411 exhibiting compan

Arrevus, a clinical stage biopharmaceutical company committed to the development of innovative therapies to treat orphan or serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ARV-1801 for the treatment of cystic fibrosis (CF). Orphan Drug Designation provides for close guidance by the FDA, potentially accelerating time to marketing approval and also includes the potential for orphan drug grants, tax credits, and 7-year mar

CPhI South East Asia – organised by Informa Markets – has been rescheduled for the newly confirmed date of 1-3 July, 2020 at the IMPACT Centre in Bangkok, Thailand. The move from the original March 4-6 date was taken after careful consideration and consultation with local government and authorities, and advice from the World Health Organisation (WHO) in regard to COVID-19. “CPhI South East Asia is a tremendous event for both Thailand and the Southeast Asian region

Inceptua Group – pharma company and service partner – today announces that Philip Gregory has joined Inceptua as Vice President, Head of Asia-Pacific, Clinical Trial Services. Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling solutions, supporting trial sponsors and helping them realize their business goals in Asia

Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced an oral presentation today highlighting Morphic’s product candidate MORF-057 at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO). MORF-057 is in development as an oral inhibitor of the α4β7 integrin, a clinically proven target for the treatment of inflammatory bowel diseases (IBD).

Tetra Bio Pharma Inc., a leader in cannabinoid-derived drug discovery and development, today announced it has signed a definitive manufacturing agreement with Vitiprints LLC, for the commercial scale production of CAUMZ™ and HCC011.  This agreement will further protect CAUMZ™ and HCC011 with four additional patents on manufacturing know-how. VITIPRINTS has developed a proprietary and patented manufacturing system, which can be used by Tetra to manufacture its CAUMZ&